Hydroxy-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors or statins are well tolerated, but associated with various statin-associated symptoms (SAS), including statin-associated muscle symptoms (SAMS), diabetes mellitus (DM), and central nervous system complaints. These are "statin-associated symptoms" because they are rare in clinical trials, making their causative relationship to statins unclear. SAS are, nevertheless, important because they prompt dose reduction or discontinuation of these life-saving mediations. SAMS is the most frequent SAS, and mild myalgia may affect 5% to 10% of statin users. Clinically important muscle symptoms, including rhabdomyolysis and statin-induced necrotizing autoimmune myopathy (SINAM), are rare. Antibodies against HMG-CoA reductase apparently provoke SINAM.
SAS are clinically important. Statin-associated muscle symptoms (SAMS), the most common statin side effect, are reported by 10% (1) to 25% (2) of patients receiving statin therapy. In an internet survey of former statin users, 60% reported SAMS (2) and 62% reported stopping statin therapy because of side effects (2) . Cessation of statin treatment is associated with worse cardiovascular outcomes. A meta-analysis of 15 statin studies observed a 45% increase in all-cause mortality and a 15% increase in CVD events in patients taking <80% of their prescribed statin therapy versus patients who were more adherent (3) . The present review will review current knowledge on SAS and suggest strategies for their management.
STATIN-ASSOCIATED MUSCLE SYMPTOMS
The American College of Cardiology (ACC) and the American Heart Association (AHA) (4), a Canadian Working Group (CWG) (5) , and the National Lipid Association (NLA) (6) have proposed definitions for SAMS ( Table 1) .
The European Phenotype Standardization
Project has also defined SAMS, with the ultimate purpose of determining associated genetic factors (7) ( Table 2 ). weakness to diagnose myositis (6) , and weakness is frequently reported by patients, but rarely objectively documented, even in those reporting statin myalgia (10) . Finally, muscle creatine released during muscle injury is metabolized to creatinine; thus, serum creatinine levels may increase in rhabdomyolysis without necessarily indicating renal injury (11) .
All definitions recognize that SAMS
Consequently, these definitions are useful for quantifying SAMS in clinical trials, but less useful in clinical practice where the clinical diagnosis of SAMS depends primarily on subjective clinical assessment. onset. This scoring system reflects both research and clinical experience, but has not been validated. Also, as STOMP was a 6-month study, the NLA criteria do not apply to patients on more prolonged statin therapy. Only STOMP (12) , to our knowledge, was designed specifically to examine skeletal muscle side effects.
THE CLINICAL DIAGNOSIS OF SAMS
Only 9.4% of the atorvastatin-treated and 4.6% of the placebo-treated study population met the study definition of SAMS, suggesting that the background noise of skeletal muscle symptoms is z5% and that the true incidence of SAMS is only z5% of the treated population. Subjects in the STOMP study were treated for only 6 months, however, and the average age was only 44 years, so higher rates of SAMS might be detected with longer treatment in older subjects. We interpreted the results to indicate more myalgia in statin users, whereas some statin trialists maintain that myalgia does not exist and that STOMP failed to prove its existence because the p value was 0.054 and not <0.05. (17) . This exercise-related increase in CK is magnified by statin treatment (18, 19) . CK levels after downhill walking in men randomly assigned to either lovastatin 40 mg daily (n ¼ 22) or placebo (n ¼ 27) increased in both the lovastatin and placebo groups, but were 62% and 77% higher the first and second days after exercise in the lovastatin group (18) .
Exercise-induced increases in CK, magnified by statin use, should always be considered in statin-treated patients presenting with increases in CK.
Rhabdomyolysis, a CK >10Â ULN, occurred in 0.10% of statin-treated and 0.04% of placebo-treated patients in randomized controlled clinical trials (15) .
Subjects were observed from 0.5 to 6.1 years, giving an extremely low yearly incidence of rhabdomyolysis (15) . The incidence of rhabdomyolysis in clinical practice has been examined using national health records (20) and health insurance databases (21, 22 ). Supporting the theory of PI3K/Akt pathway involvement in SAMS is the observation that GGPP prevents muscle injury with in vitro models of SAMS (60) . Also, atrogin-1 is increased in muscle biopsies from subjects with SAMS (66) and atrogin-1 gene expression and protein content is reduced after exercise in statin-treated subjects (67) . Opposing this concept is the fact that statins do not produce muscle atrophy and do not increase skeletal muscle protein synthesis (68) , indicating that absence of atrophy is not due to compensatory protein production.
Statins also appear to impair mitochondrial function (69). Type II mitochondrial-poor, glycolytic, skeletal muscle fibers are most vulnerable to statin Another meta-analysis (78) (56) Thus, all statins appear to produce a small increase in the relative and absolute risk of new onset DM, but this risk is greatly exceeded by their benefit. The mediating mechanism for this effect is unknown, but could be related to LDL-C reduction, and therefore might also occur with other powerful lipid-lowering agents, such as the PCSK-9 inhibitors.
EFFECTS OF STATINS ON THE CENTRAL NERVOUS SYSTEM POSSIBLE ADVERSE EFFECTS OF STATINS ON
COGNITION. Hyperlipidemia is an established risk factor for the incidence and progression of Alzheimer's disease (AD) and dementia (90) . There are, however, z60 case reports of statin-associated memory loss or dementia that often resolve with cessation of statin therapy (91) . This number of reports is low, given the widespread use of these medications, but some have suggested that statin effects on memory are easily overlooked or mistakenly attributed to aging or concurrent disease (92) . Effect in Alzheimer's Dementia) study, which found no effect of 80 mg atorvastatin in mild to moderate AD patients (108) , and a meta-analysis reporting no effect when statins were given in controlled trials for at least 6 months to patients with dementia 
OTHER POSSIBLE STATIN SIDE EFFECTS
We searched PubMed for relevant meta-analyses and reviews of possible statin side effects using a Boolean search strategy ("statin" AND "side effect"
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